Form 4: Vericel CMO Hopper Reports RSU Vesting, Stock Transactions

Vericel Corp's Chief Medical Officer, Jonathan Mark Hopper, reported the vesting of Restricted Stock Units and related common stock transactions, including tax withholdings and deferrals.

Summary

• Jonathan Mark Hopper, Chief Medical Officer of Vericel Corp (VCEL), reported multiple transactions on February 24, 2026, related to the vesting of Restricted Stock Units (RSUs).
• Acquired 350 shares of common stock from RSUs granted on February 20, 2025, which were deferred into phantom stock units under the Vericel Corporation Deferred Compensation Plan.
• Acquired 3,150 shares of common stock from RSUs granted on February 20, 2025, with a fair market value of $38.09 per share for the vested derivative securities.
• Acquired 1,500 shares of common stock from RSUs granted on February 22, 2024, which were deferred into phantom stock units under the Vericel Corporation Deferred Compensation Plan.
• Acquired 1,500 shares of common stock from RSUs granted on February 22, 2024, with a fair market value of $38.25 per share for the vested derivative securities.
• Disposed of 1,335 shares of common stock at $38.09 per share to satisfy tax withholding requirements related to RSU vesting.
• Disposed of 636 shares of common stock at $38.25 per share to satisfy tax withholding requirements related to RSU vesting.
• Following these transactions, Jonathan Mark Hopper directly beneficially owns 75,556 shares of Vericel Corp common stock, which includes shares acquired via the Issuer's 2015 Employee Stock Purchase Plan.
• Remaining RSUs from the February 20, 2025 grant will vest on February 20, 2027, February 20, 2028, and February 20, 2029.
• Remaining RSUs from the February 22, 2024 grant will vest on February 22, 2027, and February 22, 2028.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation, reflecting standard RSU vesting and tax management, which is generally neutral but indicates ongoing executive alignment.

Positives

• The vesting of Restricted Stock Units indicates continued compensation and retention of a key executive, aligning management's interests with long-term shareholder value.
• The deferral of common stock into phantom stock units under the Deferred Compensation Plan suggests a long-term commitment by the executive to the company and potential tax planning benefits.

Negatives

• The disposition of shares to cover tax withholding requirements, while standard, results in a reduction of the executive's direct shareholding.

Future Outlook

Future vesting of Restricted Stock Units is scheduled for February 20, 2027, February 20, 2028, and February 20, 2029, for grants made on February 20, 2025, and on February 22, 2027, and February 22, 2028, for grants made on February 22, 2024.

Management Comments

• The Chief Medical Officer engaged in routine transactions related to the vesting of previously granted Restricted Stock Units, including deferring a portion into a deferred compensation plan and selling shares to cover tax obligations.

Industry Context

StockSavvy.ai notes that RSU vesting and deferred compensation plans are common executive compensation practices in the biotechnology and pharmaceutical industries, aligning executive incentives with long-term company performance and providing tax-efficient remuneration.

Comparison to Industry Standards

• Executive compensation structures involving Restricted Stock Units (RSUs) and deferred compensation plans are widely adopted across the biotechnology and pharmaceutical sectors, as well as broader public markets.
• The practice of withholding shares to cover tax obligations upon RSU vesting is a common mechanism for managing executive equity awards, seen in companies like Amgen, Gilead Sciences, and Moderna.
• The use of a deferred compensation plan for equity awards is also a standard practice for executive retention and tax planning, aligning with practices observed in many S&P 500 companies.

Stakeholder Impact

• Shareholders: Provides transparency into executive stock ownership and compensation structure, confirming ongoing executive incentives.

Next Steps

• Remaining RSUs from the February 20, 2025 grant will vest on February 20, 2027, February 20, 2028, and February 20, 2029.
• Remaining RSUs from the February 22, 2024 grant will vest on February 22, 2027, and February 22, 2028.
• Shares deferred into the Vericel Corporation Deferred Compensation Plan will be payable in common stock upon the Reporting Person's elected Benefit Distribution Date.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including RSU vesting and tax-related stock sales, which are standard and do not typically alter the fundamental investment outlook for the company. It provides transparency but no new material information to warrant a change in investment recommendation.

Keywords

Vericel Corp, VCEL, Jonathan Mark Hopper, Chief Medical Officer, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Transactions, Deferred Compensation, Employee Stock Purchase Plan